Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06703190 · ClinicalTrials.gov registry record
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 1
- Enrollment target
NCT06703190 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT06703190 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across different age groups, during periods of various variant circulation, and by months since receipt of vaccine dose.
Interventions
- BIOLOGICAL Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated
- BIOLOGICAL Not vaccinated with 2024-2025 formulated COVID-19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2025-06-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06703190
The ClinicalTrials.gov registry entry for NCT06703190 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated is the first listed.
NCT06703190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06703190 about?
NCT06703190 is a clinical study titled "Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine". This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing for SARS-CoV-2, across different age groups, during periods of various ...
What is the current status of trial NCT06703190?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2024-11-25. Estimated completion is 2025-06-06.
What interventions are being tested in trial NCT06703190?
The interventions under investigation include: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated (BIOLOGICAL), Not vaccinated with 2024-2025 formulated COVID-19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06703190?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.